Answers are grounded in this paper and cite their sources.
The assessment of antigen-specific IFNγ immune response to Mycobacterium tuberculosis antigens is primarily conducted using two tests: QuantiFERON-TB (QFT) and T-SPOT.TB. The cell-mediated reaction on which both tests are based is crucial for distinguishing between latent and active tuberculosis (TB), particularly in patients receiving biological therapy. Our objective is to compare the results of patients tested with both methods, either simultaneously or within defined time intervals (up to one year). Whole venous blood (peripheral mononuclear cells, PBMCs) from patients were processed using QuantiFERON-TB Gold Plus (QFT-Plus), Qiagen, and T-SPOT.TB, Oxford Immunotec. Between January 1 and December 31, 2024, a total of 7,392 patient samples were tested in the Ramus laboratory — 6,887 with QFT-Plus and 505 with T-SPOT.TB. The analysis expectedly showed a prevalence of negative results, at 92.3% and 59.8%, compared to positive results, at 5.3% and 24.6%, respectively, for QFT-Plus and T-SPOT.TB. Low values of borderline and indeterminate results were around 2% for QFT-Plus, but 5.7% and 9.5% for T-SPOT.TB. The indeterminate results for T-SPOT.TB were reduced to 5.3% because some of them (21 patients) were on biological therapy and subsequently became negative. We analyzed the results of 94 patients who underwent both tests and 12 patients who were tested multiple times with one method during the year. Concordance between the two tests was observed in 51 individuals (54.3%): 31 had concordant positive results, 17 had concordant negative results, and 3 had indeterminate results in both tests. Discrepancies were found in 43 patients (45.7%). The analysis showed that in 61% of these cases (26/43), results shifted from indeterminate/borderline to negative or vice versa within 1 to 6 months—an acceptable variability. Among the remaining 17 individuals (39%) whose results changed from positive to negative or indeterminate, further analysis revealed that all had initiated biological therapy. Among the 12 patients repeatedly tested with T-SPOT.TB over 4–8 months, three showed consistent positive results, two showed consistent negative results, and seven experienced changes, all of whom were on biological therapy. The results from both IFNγ-based tests are comparable, with acceptable variation over time. Clinicians can rely on either method; however, significant result changes should be interpreted in light of ongoing specific or biological therapy.
No takes yet. Share an insight, caveat, or question.
Stoilov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: